RECRUITING

Speech-in-noise Perception in Autism and Fragile X

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to identify which brain regions are active during speech-in-noise perception, as well as how those regions interact. The investigators are studying brain activation during speech-in-noise in autism and controls as well as individuals with Fragile X Syndrome. The main question\[s\] it aims to answer are: 1) How does the brain's response to background noise affect a person's ability to understand speech? 2) Can visual cues improve hearing in background noise? Participants will complete the following: * hearing tests * cognitive and behavioral measures * questionnaires about their symptoms * both passive and active hearing tasks while brain activity is recorded with a neuroimaging cap Results will be compared between individuals with autism with and without Fragile X Syndrome as well as individuals without autism.

Official Title

Cortical Mechanisms of Speech in Noise Perception in Autism and Fragile X Syndrome

Quick Facts

Study Start:2023-11-10
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06088589

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. normal audiograms (PTA ≤ 20 dB HL)
  2. 2. corrected 20/20 vision (Snellen chart)
  3. 3. no history of premature birth (prior to 36 weeks gestation)
  4. 4. no medications known to affect EEG signal
  5. 5. English as the first language
  6. 1. Documented PCR/Southern Blot genetic testing confirming full mutation FXS
  7. 2. Diagnosis of Autism Spectrum Disorder, per Autism group.
  8. 1. no siblings or parents with an Autism Spectrum Disorder or Fragile X Syndrome
  9. 2. no current neurological or psychiatric diagnoses
  10. 3. IQ over 75
  1. * Hearing loss or uncorrected vision loss
  2. * history of premature birth (prior to 36 weeks gestation)

Contacts and Locations

Study Contact

Elizabeth Smith, PhD
CONTACT
513-517-1383
elizabeth.smith3@cchmc.org

Principal Investigator

Elizabeth Smith, PhD
PRINCIPAL_INVESTIGATOR
Children's Hospital Medical Center, Cincinnati

Study Locations (Sites)

Cincinnati Children'S Hospital
Cincinnati, Ohio, 45229-3026
United States

Collaborators and Investigators

Sponsor: Children's Hospital Medical Center, Cincinnati

  • Elizabeth Smith, PhD, PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-10
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2023-11-10
Study Completion Date2025-04-30

Terms related to this study

Additional Relevant MeSH Terms

  • Autism Spectrum Disorder
  • Fragile X Syndrome